EGFR and ovarian carcinoma: Additionally, TKIs targeting EGFR, such as erlotinib and gefitinib, are being evaluated in clinical trials for ovarian cancer, showing potential therapeutic efficacy particularly in ovarian cancer subtypes with EGFR overexpression or mutations (126).